[HTML][HTML] Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

L Zhong, Y Li, L Xiong, W Wang, M Wu… - Signal transduction and …, 2021 - nature.com
Due to the advantages in efficacy and safety compared with traditional chemotherapy drugs,
targeted therapeutic drugs have become mainstream cancer treatments. Since the first …

Response and resistance to BCR-ABL1-targeted therapies

TP Braun, CA Eide, BJ Druker - Cancer cell, 2020 - cell.com
Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology

MW Deininger, NP Shah, JK Altman, E Berman… - Journal of the National …, 2020 - jnccn.org
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

New treatment strategies for advanced-stage gastrointestinal stromal tumours

LR Klug, HM Khosroyani, JD Kent… - Nature reviews Clinical …, 2022 - nature.com
When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy

F Rossari, F Minutolo, E Orciuolo - Journal of hematology & oncology, 2018 - Springer
Bcr-Abl inhibitors paved the way of targeted therapy epoch. Imatinib was the first tyrosine
kinase inhibitor to be discovered with high specificity for Bcr-Abl protein resulting from t (9 …

Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia—from molecular mechanisms to clinical relevance

R Alves, AC Gonçalves, S Rutella, AM Almeida… - Cancers, 2021 - mdpi.com
Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions

AEG Osman, MW Deininger - Blood reviews, 2021 - Elsevier
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Complete hematologic and molecular response in adult patients with relapsed/refractory Philadelphia chromosome–positive B-precursor acute lymphoblastic …

G Martinelli, N Boissel, P Chevallier… - Journal of Clinical …, 2017 - ascopubs.org
Purpose Few therapeutic options are available for patients with Philadelphia chromosome–
positive (Ph+) B-precursor acute lymphoblastic leukemia (ALL) who progress after failure of …

A comprehensive review of protein kinase inhibitors for cancer therapy

R Kannaiyan, D Mahadevan - Expert review of anticancer therapy, 2018 - Taylor & Francis
Introduction: Protein kinases are involved in various cellular functions. About 2% of the
human genome encodes for protein kinases. Dysregulation of protein kinases is implicated …

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

S Yoda, JJ Lin, MS Lawrence, BJ Burke, L Friboulet… - Cancer discovery, 2018 - AACR
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy
with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor …